Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

被引：24
|
作者：
Heinzer, H [1 ]
Huland, E [1 ]
Huland, H [1 ]
机构：
[1] Univ Hamburg, Clin Eppendorf, Dept Urol, D-20246 Hamburg, Germany
来源：
WORLD JOURNAL OF UROLOGY | 2001年 / 19卷 / 02期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1007/s003450000191
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
We review the current literature on systemic therapy for patients with metastatic renal cell carcinoma. Metastatic renal cell carcinoma remains highly resistant to chemotherapy and hormonal agents not justifying its use as a single agent. Interleukin-2 immunotherapy is the most effective treatment for metastatic renal cell carcinoma available today. There is evidence that interleukin-2 improves survival and yields longlasting remissions in selected patients the optimal dose and schedule still need to be defined. Response rates in patients treated with subcutaneous interleukin-2 are similar to those achieved with high-dose bolus intravenous applications. Questions remain concerning quality of life and benefit-to-risk ratio with respect to immunotherapy in individual patients. Different routes of administration of interleukin-2 such as local application, promise to improve quality of life and survival times.
引用
收藏
页码：111 / 119
页数：9
相关论文
共 50 条
  • [11] Systemic chemotherapy for metastatic breast cancer
    Yannan Zhao
    Biyun Wang
    Oncology and Translational Medicine, 2015, 1 (05) : 226 - 232
  • [12] Systemic chemotherapy in metastatic bladder cancer
    Cakar, Burcu
    Goker, Erdem
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2012, 11 (01): : 79 - 83
  • [13] Effect of Chemotherapy, Chemoimmunotherapy, and Immunotherapy on Parameters of T Cell Exhaustion in Metastatic Non-Small Cell Lung Cancer
    Bauml, J.
    Yoon, D.
    Yan, P.
    Katz, S.
    Jeffries, S.
    Davis, C.
    Aggarwal, C.
    Cohen, R.
    Marmarelis, M.
    Singh, A.
    Ciunci, C.
    Wherry, E.
    Albelda, S.
    Langer, C.
    Huang, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S707 - S708
  • [14] CHEMOTHERAPY OF METASTATIC RENAL-CANCER
    DENIS, L
    VANOOSTEROM, A
    SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (02): : 91 - 94
  • [15] Chemoimmunotherapy in metastatic renal cell carcinoma [Chemoimmuntherapie des metastasierten nierenzellkarzinoms]
    Atzpodien J.
    Reitz M.
    Der Onkologe, 2004, 10 (9): : 934 - 940
  • [16] Substituted titanocenes:: chemotherapy against metastatic renal-cell cancer?
    Claffey, J.
    Hogan, M.
    Muller-Bunz, H.
    Pampillon, C.
    Tacke, M.
    BJU INTERNATIONAL, 2007, 100 : 21 - 21
  • [17] Systemic chemotherapy in inoperable or metastatic bladder cancer
    Bamias, A
    Tiliakos, I
    Karali, M
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2006, 17 (04) : 553 - 561
  • [18] Systemic chemotherapy options for metastatic bladder cancer
    Siefker-Radtke, Arlene
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) : 877 - 885
  • [19] SURVEY OF CHEMOTHERAPY OF METASTATIC RENAL-CANCER
    KUHBOCK, J
    SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (02): : 87 - 90
  • [20] Cytotoxic chemotherapy for metastatic renal cell carcinoma
    Stadler, WM
    UROLOGE A, 2004, 43 (Suppl 3): : S145 - S146
12345